Foresight Group Ltd Liability Partnership purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 48,725 shares of the company's stock, valued at approximately $954,000.
A number of other institutional investors and hedge funds have also bought and sold shares of GMAB. Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after buying an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after buying an additional 1,070 shares in the last quarter. Barclays PLC lifted its holdings in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after buying an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Genmab A/S during the 4th quarter valued at approximately $60,000. Finally, Brooklyn Investment Group grew its holdings in shares of Genmab A/S by 729.3% during the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock worth $83,000 after acquiring an additional 3,734 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Price Performance
Shares of NASDAQ:GMAB opened at $27.73 on Thursday. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $28.03. The company has a market cap of $17.79 billion, a P/E ratio of 13.93, a PEG ratio of 1.62 and a beta of 0.93. The stock's fifty day moving average price is $23.24 and its 200-day moving average price is $21.57.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.
Analyst Ratings Changes
GMAB has been the subject of a number of research reports. Zacks Research downgraded Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. HC Wainwright boosted their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Truist Financial lifted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $39.25.
Get Our Latest Research Report on GMAB
Genmab A/S Company Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
